John Robbins
Medical · Winston Salem, NCNPI 1952350415
Payments from drug & device makers
Across 1,657 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Livanova USA, Inc.$2K
- UCB, Inc.$1K
- SK Life Science, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- plus $15K from 54 others
What the payments were for
- Speaking & faculty fees$2341%
- Travel & lodging$1,0364%
- Food & beverage$24,49794%
- Education$2661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,568
- AJOVY$120
How this compares
$26,033 in reported general payments places this provider in the 95th percentile of 878 medical providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 147 | $174,436 |
| AustedoDeutetrabenazine | 11 | $173,439 |
| Kesimpta PenOfatumumab | 15 | $131,191 |
| VumerityDiroximel Fumarate | 12 | $106,388 |
| AptiomEslicarbazepine Acetate | 41 | $84,891 |
| Xtampza ErOxycodone Myristate | 85 | $80,822 |
| Nurtec OdtRimegepant Sulfate | 32 | $66,783 |
| UbrelvyUbrogepant | 43 | $64,513 |
| QuliptaAtogepant | 57 | $63,017 |
| ValtocoDiazepam | 28 | $51,731 |
| NuedextaDextromethorphan Hbr/Quinidine | 19 | $31,108 |
| Aimovig AutoinjectorErenumab-Aooe | 35 | $26,128 |
| NeuproRotigotine | 15 | $12,274 |
| BelbucaBuprenorphine Hcl | 11 | $10,081 |
| Emgality PenGalcanezumab-Gnlm | 13 | $8,849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $1,405 | $174,436147 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $2,232 | $173,43911 claims |
| AbbVieUbrelvy, Qulipta, Savella | $2,646 | $132,916111 claims |
| BiogenVumerity | $1,232 | $106,38812 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $64 | $90,90496 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $461 | $84,89141 claims |
| PfizerNurtec Odt | $656 | $66,78332 claims |
| Neurelis, Inc.Valtoco | $1,027 | $51,73128 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $78 | $31,10819 claims |
| UCB, Inc.Neupro | $1,491 | $12,27415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 medical providers in North Carolina.
Other medical in Winston Salem
- Amanda ZimmermanWinston Salem$48K
- Christopher GeorgeffWinston Salem$13K
- Victoria HinkelWinston Salem$12K
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$269K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- David TaylorMorehead City$40K
- Katherine CardSalisbury$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.